Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs

Journal of Urology

Volumn 190, Issue 2, 2013, Pages 799-806

  Mochida, Hideki ^a,b   Yano, Koji ^a,b   Inoue, Hirotaka ^a,b   Yee, Shiyin ^a,b   Noto, Tsunehisa ^a,b   Kikkawa, Kohei ^a,b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b Menlo Park and VIVUS   (United States)

Author keywords

avanafil; erectile dysfunction; hypotension; penis; retina

Indexed keywords

AVANAFIL; GLYCERYL TRINITRATE; SILDENAFIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CAROTID ARTERY; DOG; DRUG SAFETY; ELECTRORETINOGRAM; ERECTILE DYSFUNCTION; HEMODYNAMICS; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RETINA;

EID: 84880040137     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.01.017     Document Type: Article

References (25)

1. U. Walter Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system Rev Physiol Biochem Pharmacol 113 1989 41
2. J.D. Corbin, M.K. Thomas, L. Wolfe New insights into cGMP action Adv Second Messenger Phosphoprotein Res 24 1990 411
3. T.M. Lincoln, T.L. Cornwell Intracellular cyclic GMP receptor proteins FASEB J 7 1993 328
4. S.D. Rybalkin, C. Yan, K.E. Bornfeldt Cyclic GMP phosphodiesterases and regulation of smooth muscle function Circ Res 93 2003 280
5. S.H. Francis, M.A. Blount, J.D. Corbin Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions Physiol Rev 91 2011 651
6. C.S. Lin, G. Lin, Z.C. Xin Expression, distribution and regulation of phosphodiesterase 5 Curr Pharm Des 12 2006 3439
7. K. Omori, J. Kotera Overview of PDEs and their regulation Circ Res 100 2007 309
8. T. Noto, H. Inoue, T. Ikeo Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs J Pharmacol Exp Ther 294 2000 870
9. T.J. Bivalacqua, H.C. Champion, W.J. Hellstrom Pharmacotherapy for erectile dysfunction Trends Pharmacol Sci 21 2000 484
10. J. Kotera, H. Mochida, H. Inoue Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction J Urol 188 2012 668
11. D.J. Webb, G.J. Muirhead, M. Wulff Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina J Am Coll Cardiol 36 2000 25
12. R.A. Kloner, A.M. Hutter, J.T. Emmick Time course of the interaction between tadalafil and nitrates J Am Coll Cardiol 42 2003 1855
13. E. Bischoff Potency, selectivity, and consequences of nonselectivity of PDE inhibition Int J Impot Res 16 suppl 2004 S11
14. X. Zhang, Q. Feng, R.H. Cote Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors Invest Ophthalmol Vis Sci 46 2005 3060
15. H. Mochida, T. Noto, H. Inoue T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs Eur J Pharmacol 485 2004 283
16. M. Kaburaki, H. Narita, H. Yabana Cardiovascular effect of a new 1,5-benzothiazepine derivative TA-993 in anesthetized dogs J Cardiovasc Pharmacol 31 1998 240
17. S. Murata, K. Kikkawa, H. Yabana Cardiovascular effects of a new 1,5-benzothiazepine calcium antagonist in anesthetized dogs Arzneimittelforschung 38 1988 521
18. F. Giuliano, G. Jackson, F. Montorsi Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database Int J Clin Pract 64 2010 240
19. R. Wang, A.L. Burnett, W.H. Heller Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: Implications for clinical safety and improved tolerability J Sex Med 9 2012 2122
20. I. Goldstein, L.A. Jones, L.H. Belkoff Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus Mayo Clin Proc 87 2012 843
21. A.M. Laties Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date Drug Saf 32 2009 1
22. T. Reffelmann, R.A. Kloner Cardiovascular effects of phosphodiesterase 5 inhibitors Curr Pharmacol Des 12 2006 3485
23. H. Mochida, H. Inoue, M. Takagi Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta Eur J Pharmacol 440 2002 45
24. Highlights of Prescribing Information. Revised April 2012. Reference ID: 3123097. Silver Spring: United States Food and Drug Administration, United States Department of Health and Human Services 2012.
25. Nehra A, Swearingen D, Dietrich J, et al. Hemodynamic effects of co-administration of avanafil and glyceryl trinitrate. Presented at meeting of Sexual Medicine Society of North America, November 17-20, 2005, New York, New York; abstract 112.